Mounjaro and Tirzepatide Pens, Strengths and Country-Label Differences
Understand how tirzepatide works, what outcomes to expect, how pen instructions differ and which safety questions need a clinician’s review.
Reference table
Tirzepatide reference table
Read the prescribed dose and the manufacturer’s instructions together for the exact supplied presentation.
Reading a pen strength correctly
| Information | Why it matters | Check against |
|---|---|---|
| mg per delivered dose | Identifies the prescribed dose | Prescription and exact pack |
| mL per delivered dose | Part of the device specification | Manufacturer instructions |
| Single-dose or multi-dose device | Changes use and disposal instructions | Named pen or vial leaflet |
| Total pen contents | May cover more than one dose | Exact product information |
The named US and UK reference information supports the relevant sections below.
What Mounjaro does and which uses apply
Mounjaro contains tirzepatide. A dual agonist activates two receptor types, GIP and GLP-1, involved in appetite and blood-glucose regulation. Tirzepatide helps the body release insulin when glucose is elevated, reduces glucagon and delays stomach emptying. Reduced appetite can make it easier to eat less.
The August 2026 US label covers type 2 diabetes from age 10 and reduction of major cardiovascular events in high-risk adults with type 2 diabetes. UK and EU Mounjaro information also covers adult weight management with diet and activity support. UK weight eligibility starts at BMI 30, or BMI 27 with a weight-related condition. The local label and clinical assessment determine eligibility. Tirzepatide versus semaglutide explains how reference brands and treatment goals differ.
How long results take and what trials show
Weight-management treatment is assessed over months. An early appetite change cannot predict the eventual result. For diabetes, glucose records and follow-up tests help assess response. Agree with the clinician which outcomes matter and when to review them.
In SURMOUNT-1, 2,539 adults with obesity, or overweight and a complication, received tirzepatide or placebo alongside lifestyle support. Participants did not have diabetes. At 72 weeks, average weight reductions were 15.0%, 19.5% and 20.9% with the 5, 10 and 15 mg study regimens respectively, compared with 3.1% for placebo. These are trial-group averages under a defined programme. They cannot forecast an individual result or establish the same outcome in people with diabetes.
Why treatment usually increases gradually
Escalation gives the treatment team time to assess tolerance and response. Nausea, vomiting and diarrhoea occur particularly during escalation and often decrease over time. A higher-strength pen should follow a prescribing decision. Ask before progressing if symptoms are affecting eating or drinking.
The plan also needs review after an interruption. Keep the prescribed dose and injection dates recorded, and contact the dispensing team if the next pen differs from the prescription.
Reading milligrams, millilitres and the device
Milligrams describe the amount of tirzepatide. Millilitres describe liquid volume. The UK 2.5 mg KwikPen delivers 2.5 mg in each 0.6 mL dose and provides four doses. Its total labelled contents differ from the amount injected on one occasion.
Single-dose pens, multi-dose pens and vials have their own instructions. Obtain a device demonstration, use the prescribed presentation and follow its disposal instructions. Never share a pen, even with a changed needle, or extract leftover liquid to improvise another dose.
A missed injection or a different weekly day
The UK Mounjaro KwikPen SmPC says a missed dose may be taken within four days. After more than four days, skip it and take the next dose on the usual day. Its weekly administration day may be changed provided at least three days separate two doses.
These instructions concern the named UK product. Check the supplied leaflet and ask a pharmacist if the elapsed time, product or restart plan is uncertain.
Common side effects and practical ways to cope
Nausea, diarrhoea, constipation, vomiting, indigestion and abdominal discomfort can occur. Cambridge University Hospitals advises eating slowly, stopping when full and trying bland, low-fat foods for nausea. Sip fluids regularly, following any existing fluid restriction. Persistent difficulty eating or drinking needs a treatment review.
Keep a brief record of symptoms, meals and injection dates. The prescriber can assess severity and whether escalation should wait. Do not add another weight-loss product or change the prescription to manage the problem yourself.
Symptoms that need prompt or urgent care
Get urgent medical assessment for severe, persistent abdominal pain, especially pain spreading to the back, because pancreatitis needs consideration. Repeated vomiting, inability to retain fluids, faintness or markedly reduced urine can indicate dehydration and possible kidney problems. Upper abdominal pain with fever or jaundice also needs assessment.
Swelling of the face or throat or breathing difficulty requires emergency help. Tell the treating team about severe stomach-emptying problems and diabetic eye disease before treatment. The US boxed warning concerns thyroid C-cell tumours seen in rats, with human risk uncertain. Its label contraindicates Mounjaro with a personal or family history of medullary thyroid carcinoma or MEN 2.
Other medicines and oral contraception
Insulin and sulphonylureas can increase low-blood-glucose risk with tirzepatide. The treating team may need to adjust those medicines and explain monitoring. Provide a full list of prescriptions and supplements because delayed stomach emptying can affect some oral medicines.
UK safety advice tells oral-contraceptive users to add a barrier method for four weeks after starting Mounjaro and four weeks after each dose increase, or discuss switching to non-oral contraception. Ask for advice if vomiting or diarrhoea may also affect the pill.
Pregnancy planning and planned procedures
UK guidance advises stopping tirzepatide at least one month before a planned pregnancy. Contact the prescriber promptly if pregnancy occurs. Breastfeeding decisions require an individual discussion using current local information.
Tell surgical, anaesthetic and endoscopy teams that you take tirzepatide. Delayed stomach emptying can increase aspiration risk during general anaesthesia or deep sedation. Follow the procedural team’s instructions about treatment and fasting.
Monitoring progress, nutrition and activity
Reviews should consider treatment goals, side effects, nutrition and daily function as well as weight. Discuss a slower trend through the Weight-loss plateau guide. Cambridge University Hospitals highlights adequate nutrition and maintaining activity during treatment. Ask about dietary support if reduced appetite makes regular balanced meals difficult.
Strength training during weight loss discusses preserving function and muscle. Hair shedding after weight loss explains another concern worth assessing rather than treating with supplements automatically.
Storage and checking the proposed product
The UK KwikPen SmPC specifies refrigeration at 2–8°C and no freezing. After first use, it allows up to 30 days unrefrigerated at temperatures no higher than 30°C, followed by disposal. Another presentation needs its own storage and transport instructions. Ask a pharmacist about a temperature excursion or damaged pack.
For a supply enquiry, confirm the exact brand, device, batch, expiry and receiving-country requirements. Existing catalogue pages are Tirzepatide 2.5 mg Prefilled Pen Listing, Tirzepatide 5 mg Prefilled Pen Listing and Tirzepatide 7.5 mg Prefilled Pen Listing.
Export product support
Need product, pack, and documentation details?
Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.
Common questions
Is Mounjaro the same as tirzepatide?
Tirzepatide is the active ingredient. Mounjaro is a brand. Confirm the exact brand and presentation on the pack.
How quickly should I expect weight loss?
Response varies. The cited trial measured its main outcome at 72 weeks. Arrange earlier reviews for tolerance, nutrition and progress.
Can I increase the strength because appetite has returned?
Discuss the pattern with the prescriber. Tolerability, response and the treatment goal guide any change.
What should I do if I miss my UK KwikPen dose?
Its SmPC allows administration within four days. After that, skip the missed dose and resume the usual day. Ask a pharmacist about uncertainty.
Can I use liquid remaining after the four KwikPen doses?
The UK instructions say to discard excess solution. Follow the device instructions and report a malfunction.
Does tirzepatide affect the contraceptive pill?
UK advice recommends extra barrier protection for four weeks after starting and after dose increases, or a non-oral method.
Does Mounjaro replace nutrition and activity support?
Weight-management treatment includes dietary and activity support. Agree an achievable plan that protects adequate nutrition.
Can the same storage rule be used for every tirzepatide product?
Follow the actual leaflet. Multi-dose KwikPens, single-dose pens and vials can have different instructions.
Important medical note
This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.
References
- Lilly US Mounjaro prescribing information, revised August 2026
- UK Mounjaro KwikPen SmPC, text revised 29 August 2026
- NHS tirzepatide medicine information
- EMA Mounjaro European public assessment information
- SURMOUNT-1 primary trial report, New England Journal of Medicine, 2022
- NICE practical guide to prescribing, reviewing and stopping tirzepatide
- Cambridge University Hospitals tirzepatide patient information
- MHRA GLP-1 medicine safety guidance, updated 5 February 2026
- NIDDK prescription medicines for overweight and obesity